APA (7th ed.) Citation

SY, Y., SH, L., JH, K., SS, L., AO, K., & JS, L. (2025). Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial". Clinical and molecular hepatology, 31(1), e84. https://doi.org/10.3350/cmh.2024.0830

Chicago Style (17th ed.) Citation

SY, Yim, Lee SH, Kim JH, Lee SS, Kaseb AO, and Lee JS. "Correspondence to Editorial 2 on "Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial"." Clinical and Molecular Hepatology 31, no. 1 (2025): e84. https://doi.org/10.3350/cmh.2024.0830.

MLA (9th ed.) Citation

SY, Yim, et al. "Correspondence to Editorial 2 on "Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial"." Clinical and Molecular Hepatology, vol. 31, no. 1, 2025, p. e84, https://doi.org/10.3350/cmh.2024.0830.